ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0611

Subclinical Atherosclerosis Is Associated with Future Cardiovascular Events in Systemic Lupus Erythematosus Patients at Apparent Low Risk for Cardiovascular Disease: A Longitudinal Prospective Study

Arthur Mageau1, Marie-Paule Chauveheid2, Chrystelle Francois2, Thomas Papo1 and Karim Sacré1, 1Université Paris Cité, Paris, France, 2Assistance Publique Hôpitaux de Paris, Paris, France

Meeting: ACR Convergence 2024

Keywords: Atherosclerosis, Cardiovascular, Carotid Artery Disease, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Cardiovascular events (CVE) are the leading cause of mortality for patients living with systemic lupus erythematosus (SLE). Besides the traditional cardiovascular risk factors, the impact of subclinical atherosclerosis on the clinical cardiovascular risk is yet to be determined in the specific population. Our aim was to evaluate the association between subclinical atherosclerosis defined as the presence of an atherosclerotic carotid plaque > 1.5 mm in thickness, and the risk of future cardiovascular events in SLE.

Methods: We performed a prospective study including consecutive patients with SLE followed in our reference center. We excluded patients with a known coronary disease or symptoms suggestive of cardiovascular disease (angina, arrhythmia, congestive heart failure, stroke, and peripheral arterial disease). All patients were evaluated for carotid plaque by a single evaluator. At inclusion, we collected demographic characteristics, morphometric parameters such as body mass index (BMI) and waist circumference, disease characteristics and treatment history. The main outcome was a cardiovascular event defined as the occurrence during a 11-years follow-up of myocardial infarction, ischemic stroke or symptomatic peripheral arterial disease. We examined the association between carotid plaque and cardiovascular event onset using uni- and multivariable logistic regression using Firth’s correction for separated data.

Results: We included 63 SLE patients (82.5% female), with an age of (median [1st quartile-3rd quartile]) 39 [32-44.5] years. Among them, 24 (38.1%) had a carotid plaque > 1.5 mm at baseline and 7 (11.1 %) experienced a cardiovascular event during a median follow-up of 10.7 [8.2-11.0] years. All the cardiovascular events occurred in the group of patients with a carotid plaque at baseline. The univariable analysis of the factors associated with the occurrence of a cardiovascular event are presented in Table 1 (see below). The survival without cardiovascular event in this population, according to the presence of a carotid plaque at baseline is presented as a Kaplan-Meier curve in Figure 1 (see below). In the multivariable analysis, we observed that, after adjusting for the Framingham score and the body mass index, the presence of a carotid plaque remained significantly associated with the occurrence of a cardiovascular event : odds ratio [95% confidence interval] = 15.6 [1.02, 2226]; p= 0.048.

Conclusion: Subclinical atherosclerosis defined as a carotid plaque > 1.5 mm is significantly associated with the clinical cardiovascular risk in SLE. Subclinical atherosclerosis should be regularly assessed in this population as part of the global cardiovascular risk evaluation.

Supporting image 1

Factors associated with cardiovascular events during follow up
BMI: body mass index; Framingham: Framingham cardiovascular risk score; SLE: systemic lupus erythematosus, eGFR: estimated glomerular filtration rate; SLEDAI: systemic lupus erythematosus disease activity index; Ab: antibody; CS: corticosteroids (prednisone equivalent).

Supporting image 2

Survival without cardiovascular event according to the presence of a plaque at baseline.
p-value is calculated using the log-rank test.


Disclosures: A. Mageau: None; M. Chauveheid: None; C. Francois: None; T. Papo: None; K. Sacré: None.

To cite this abstract in AMA style:

Mageau A, Chauveheid M, Francois C, Papo T, Sacré K. Subclinical Atherosclerosis Is Associated with Future Cardiovascular Events in Systemic Lupus Erythematosus Patients at Apparent Low Risk for Cardiovascular Disease: A Longitudinal Prospective Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/subclinical-atherosclerosis-is-associated-with-future-cardiovascular-events-in-systemic-lupus-erythematosus-patients-at-apparent-low-risk-for-cardiovascular-disease-a-longitudinal-prospective-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subclinical-atherosclerosis-is-associated-with-future-cardiovascular-events-in-systemic-lupus-erythematosus-patients-at-apparent-low-risk-for-cardiovascular-disease-a-longitudinal-prospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology